Bringing Difficult Membrane Proteins Into Compound Screening: Salipro Technology Appears in Scientific Reports

Proteins on the cell membrane control signal transmission, ion channels, and the entry and exit of drugs, making them among the most desired and most difficult targets for many drugs. The difficulty is that once these proteins leave the lipid membrane, they often lose their original conformation or function; meanwhile, large-scale compound screening requires targets that are stable, reproducible, and able to withstand experimental workflows. Salipro Biotech recently announced that a study published in Scientific Reports attempted to connect these two requirements.

According to the company’s press release and the journal paper, the research team integrated Salipro’s lipid nanoparticle platform with DNA-encoded library (DEL) screening for early drug discovery targeting membrane proteins. DEL technology can test large numbers of DNA-tagged small molecules at once. In the past, it was easier to apply to soluble proteins, while the challenges increased markedly when facing complex membrane proteins that require a membrane environment to maintain their structure.

The study used Pannexin 1 (PANX1) as a model system. PANX1 is a type of membrane channel protein involved in the passage of ions and small molecules across the cell membrane, which also makes it attractive for drug development. The paper states that the team used the Salipro DirectMX method to prepare functional PANX1 nanoparticles and conducted DEL screening in a detergent-free format closer to the natural membrane environment.

The study did not stop at the step of “finding candidate molecules.” According to the paper abstract and the company’s description, post-screening hit compounds were further confirmed for binding by surface plasmon resonance, and structural clues to possible binding sites were obtained through cryo-electron microscopy. Electrophysiology experiments showed that some compounds could inhibit PANX1-mediated ion conduction in a dose-dependent manner. These validations brought the work closer to a traceable starting point in the drug discovery process, rather than merely serving as a screening demonstration.

Participating organizations included Salipro Biotech, AstraZeneca, DyNAbind, the University of Copenhagen, and Thermo Fisher Scientific, among others. This combination also reflects the interdisciplinary nature of membrane protein drug discovery: protein engineering, lipid nanoparticles, compound library design, structural biology, and functional testing must be connected with one another, and any single platform alone is usually insufficient to complete the entire validation chain.

However, this remains a proof-of-concept study, not a clinical result or a direct drug development outcome. PANX1 is a model target and does not necessarily mean that all membrane proteins can be prepared, screened, and validated with the same smoothness. DEL hit molecules also usually still need to go through affinity, selectivity, cellular activity, medicinal chemistry optimization, and safety evaluation. The paper also discloses that some authors have current or former employment relationships with companies or related technologies, as well as patent interests, and these backgrounds should be taken into account when interpreting the study’s industrial significance.

If the process can subsequently be reproduced across more types of membrane proteins, its value will not lie in claiming the discovery of a new drug, but in opening an entry point for a group of targets that have long been difficult to bring into high-throughput screening. For drug development, whether verifiable molecules can be screened at an early stage using membrane proteins in a state closer to their natural condition often determines whether a difficult target has a chance to move from a biological hypothesis toward a genuine chemical starting point.